BNP PARIBAS FINANCIAL MARKETS - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 98 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 6.05 and the average weighting 0.4%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$119,042
-29.4%
13,794
-15.3%
0.00%
Q2 2023$168,519
-19.1%
16,282
-15.2%
0.00%
Q1 2023$208,363
-57.4%
19,204
-56.0%
0.00%
-100.0%
Q4 2022$489,203
-99.7%
43,601
+173.2%
0.00%
Q3 2022$161,804,000
-83.6%
15,957
-85.3%
0.00%
-100.0%
Q2 2022$984,369,000
-17.1%
108,650
-12.5%
0.00%0.0%
Q1 2022$1,187,677,000
+40.1%
124,234
+61.9%
0.00%
+100.0%
Q4 2021$847,811,000
+961.8%
76,725
+611.1%
0.00%
Q3 2021$79,846,000
+165.3%
10,790
+420.5%
0.00%
Q2 2021$30,100,000
-79.0%
2,073
-70.5%
0.00%
Q1 2021$143,441,000
-17.2%
7,028
-27.9%
0.00%
Q4 2020$173,240,000
+6.5%
9,749
-11.4%
0.00%
Q3 2020$162,694,000
+154.1%
11,004
+260.7%
0.00%
Q2 2020$64,040,000
-82.6%
3,051
-80.8%
0.00%
-100.0%
Q1 2020$368,165,000
+132.0%
15,931
+159.9%
0.00%
Q4 2019$158,680,000
+3.4%
6,129
-22.2%
0.00%
Q3 2019$153,483,000
+62.3%
7,879
+36.1%
0.00%
Q2 2019$94,567,000
-58.1%
5,791
-41.9%
0.00%
Q1 2019$225,907,000
+770.6%
9,965
+882.7%
0.00%
Q4 2018$25,948,000
-66.6%
1,014
-57.3%
0.00%
Q3 2018$77,657,000
+55.9%
2,377
+8.2%
0.00%
Q2 2018$49,828,000
-77.3%
2,197
-75.8%
0.00%
Q1 2018$219,705,000
-9.1%
9,060
+4.6%
0.00%
Q4 2017$241,667,000
+45.0%
8,665
+78.0%
0.00%
Q3 2017$166,680,000
-18.8%
4,868
-5.5%
0.00%
-100.0%
Q2 2017$205,216,000
+625.7%
5,151
+570.7%
0.00%
Q1 2017$28,278,000
-67.1%
768
-71.5%
0.00%
Q4 2016$85,853,000
-21.2%
2,693
-10.5%
0.00%
Q3 2016$109,010,000
+235.7%
3,008
+110.2%
0.00%
Q2 2016$32,469,000
-68.1%
1,431
-76.9%
0.00%
Q4 2015$101,650,000
+77.2%
6,202
+18.8%
0.00%
Q3 2015$57,357,000
+93.1%
5,219
+128.8%
0.00%
Q2 2015$29,699,000
+205.7%
2,281
+307.3%
0.00%
Q1 2015$9,716,000
-70.0%
560
-60.2%
0.00%
Q3 2014$32,408,0001,4060.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2019
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders